EGFR and non-small cell lung carcinoma: One of the most important achievements in NSCLC research has been the development of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which have increased the OS of patients with advanced-stage EGFR-mutated NSCLC to approximately 22–34 months [5–9].